Puma Biotechnology (PBYI) 205.26 $PBYI
Biotech Stocks: What's Hot, What's Not - As Seen By Market-Makers, Their Clients
Peter F. Way, CFA - at Seeking Alpha - Wed Feb 11, 11:37AM CST
MDVN: 104.71 (+0.67), BLUE: 90.70 (+0.93), BIIB: 391.66 (-0.45), GILD: 101.90 (+1.10), ALXN: 182.29 (+6.02), TGTX: 13.13 (-0.19), TKMR: 21.45 (-0.22), ANAC: 40.76 (-0.07), PBYI: 205.26 (+2.75), REGN: 402.40 (+0.66)
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Puma Biotechnology, Inc.
PR Newswire - Tue Feb 10, 7:45AM CST
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Puma Biotechnology, Inc. ("Puma Biotechnology" or the "Company"
(NYSE: PBYI -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.
PBYI: 205.26 (+2.75)
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Puma Biotechnology, Inc. (PBYI) To Contact The Firm
PR Newswire - Mon Feb 09, 3:00PM CST
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Puma Biotechnology, Inc. ("Puma" or the "Company" (NYSE: PBYI).
PBYI: 205.26 (+2.75)
3 All-or-Nothing Biotech Stocks We're Closely Watching
Motley Fool Staff - Motley Fool - Mon Feb 09, 7:10AM CST
There may be no other industry as prone to hit-or-miss investments as biotechnology. An astounding 90% of drugs that enter phase 1 clinical trials never reach commercialization, and that means failure is far more common than success. As a result,...
JNJ: 99.62 (+1.18), ESPR: 67.13 (-0.33), GERN: 3.03 (unch), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), INCY: 75.94 (+0.28), AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66), PBYI: 205.26 (+2.75)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Puma Biotechnology, Inc. - PBYI
PR Newswire - Fri Feb 06, 1:31PM CST
Pomerantz LLP is investigating claims on behalf of investors of Puma Biotechnology, Inc. ("Puma" or the "Company" (NYSE: PBYI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.
PBYI: 205.26 (+2.75)
Puma Biotechnology to Present at Leerink Global Healthcare Conference
Business Wire - Thu Feb 05, 3:05PM CST
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 8:30 a.m. EST on Thursday, February 12, at the 2015 Leerink Global Healthcare Conference. The conference will be held at the Waldorf Astoria Hotel in New York City.
PBYI: 205.26 (+2.75)
Puma Biotechnology Closes $218 Million Public Offering of Common Stock
Business Wire - Tue Jan 27, 1:36PM CST
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced the closing of an underwritten registered public offering of 1,150,000 shares of its common stock at a price to the public of $190.00 per share. The shares of common stock issued in the offering included 150,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. The net proceeds from the offering were approximately $205 million, after deducting the underwriting discount and estimated offering expenses payable by the Company.
JPM: 59.67 (+0.10), PBYI: 205.26 (+2.75)
Puma Biotechnology's underwriters exercise option to purchase 150,000 additional shares
M2 - Fri Jan 23, 8:00PM CST
Biopharmaceutical company Puma Biotechnology (NYSE
BYI) said on Thursday that the underwriters of its public offering have elected to exercise in full their option to purchase up to an additional 150,000 shares of common stock at the public offering price, less the underwriting discount.
PBYI: 205.26 (+2.75)
NYSE stocks posting largest percentage increases
AP - Fri Jan 23, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at the close of trading:
AVP: 9.08 (+0.39), ORB: 28.85 (+0.21), IPHI: 19.17 (-1.48), KEY: 14.11 (-0.08), ATEN: 4.14 (-0.09), CYN: 90.32 (+0.49), WBS: 34.26 (+0.22), LUV: 43.30 (-0.20), RICE: 19.13 (-0.22), P: 15.44 (+0.45), KBR: 18.18 (+0.20), SYF: 32.80 (-0.81), DLX: 67.06 (-0.02), PBYI: 205.26 (+2.75)
Puma Biotechnology Announces Underwriters' Full Exercise of Option to Purchase Additional Shares
Business Wire - Thu Jan 22, 6:10PM CST
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that the underwriters for its public offering of 1,000,000 shares of its common stock at $190.00 per share have elected to exercise in full their option to purchase up to an additional 150,000 shares of common stock at the public offering price, less the underwriting discount. The closing for the additional purchase of 150,000 shares is expected to take place concurrently with the closing for the initial purchase of 1,000,000 shares on January 27, 2015, subject to customary closing conditions.
JPM: 59.67 (+0.10), PBYI: 205.26 (+2.75)
Southwest Airlines and eBay are big market movers
AP - Thu Jan 22, 3:28PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
AXP: 78.08 (-2.40), ACTG: 13.13 (+0.04), UNH: 109.44 (-0.40), FDO: 77.86 (+0.31), LUV: 43.30 (-0.20), NFLX: 466.10 (+9.37), DFS: 59.89 (+0.46), NSP: 48.91 (+1.20), EGO: 4.94 (+0.10), AMD: 3.15 (+0.03), ELD.TO: 6.15 (+0.09), VZ: 49.31 (-0.21), AAPL: 127.08 (+0.62), PBYI: 205.26 (+2.75)
4 Stocks Spiking on Unusual Volume: Puma Biotech, Nexstar and More
at The Street - Thu Jan 22, 12:48PM CST
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
PFS: 18.64 (+0.09), NXST: 53.62 (+0.02), PBYI: 205.26 (+2.75), ADPT: 34.87 (+0.58)
Puma Bio prices equity offering
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 6:24AM CST
PBYI: 205.26 (+2.75)
Puma Biotechnology Prices Public Offering of Common Stock
Business Wire - Wed Jan 21, 6:13PM CST
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced the pricing of an underwritten registered public offering of 1,000,000 shares of its common stock at $190.00 per share. The Company has granted the underwriters for the offering a 30-day option to purchase up to 150,000 additional shares of its common stock at the public offering price, less the underwriting discount. The offering is expected to close on or about January 27, 2015, subject to customary closing conditions.
JPM: 59.67 (+0.10), PBYI: 205.26 (+2.75)
Puma Bio initiates equity offering
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 3:31PM CST
PBYI: 205.26 (+2.75)
Puma Biotechnology Announces Proposed Public Offering
Business Wire - Tue Jan 20, 3:23PM CST
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, today announced that it is commencing an underwritten registered public offering of 1,000,000 shares of its common stock. Puma Biotechnology intends to grant the underwriters a 30-day option to purchase up to an additional 150,000 shares of its common stock. All of the shares are being offered by Puma Biotechnology.
JPM: 59.67 (+0.10), PBYI: 205.26 (+2.75)
Biotech Stocks: What's Hot, What's Not - As Seen By Market-Makers, Their Clients
Peter F. Way, CFA - at Seeking Alpha - Wed Feb 11, 11:37AM CST
MDVN: 104.71 (+0.67), BLUE: 90.70 (+0.93), BIIB: 391.66 (-0.45), GILD: 101.90 (+1.10), ALXN: 182.29 (+6.02), TGTX: 13.13 (-0.19), TKMR: 21.45 (-0.22), ANAC: 40.76 (-0.07), PBYI: 205.26 (+2.75), REGN: 402.40 (+0.66)
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Puma Biotechnology, Inc.
PR Newswire - Tue Feb 10, 7:45AM CST
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Puma Biotechnology, Inc. ("Puma Biotechnology" or the "Company"
(NYSE: PBYI -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484. PBYI: 205.26 (+2.75)
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Puma Biotechnology, Inc. (PBYI) To Contact The Firm
PR Newswire - Mon Feb 09, 3:00PM CST
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Puma Biotechnology, Inc. ("Puma" or the "Company"
(NYSE: PBYI). PBYI: 205.26 (+2.75)
3 All-or-Nothing Biotech Stocks We're Closely Watching
Motley Fool Staff - Motley Fool - Mon Feb 09, 7:10AM CST
There may be no other industry as prone to hit-or-miss investments as biotechnology. An astounding 90% of drugs that enter phase 1 clinical trials never reach commercialization, and that means failure is far more common than success. As a result,...
JNJ: 99.62 (+1.18), ESPR: 67.13 (-0.33), GERN: 3.03 (unch), PFE: 34.64 (-0.23), MRK: 58.81 (-0.07), INCY: 75.94 (+0.28), AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66), PBYI: 205.26 (+2.75)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Puma Biotechnology, Inc. - PBYI
PR Newswire - Fri Feb 06, 1:31PM CST
Pomerantz LLP is investigating claims on behalf of investors of Puma Biotechnology, Inc. ("Puma" or the "Company"
(NYSE: PBYI). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. PBYI: 205.26 (+2.75)
Puma Biotechnology to Present at Leerink Global Healthcare Conference
Business Wire - Thu Feb 05, 3:05PM CST
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 8:30 a.m. EST on Thursday, February 12, at the 2015 Leerink Global Healthcare Conference. The conference will be held at the Waldorf Astoria Hotel in New York City.
PBYI: 205.26 (+2.75)
Puma Biotechnology Closes $218 Million Public Offering of Common Stock
Business Wire - Tue Jan 27, 1:36PM CST
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced the closing of an underwritten registered public offering of 1,150,000 shares of its common stock at a price to the public of $190.00 per share. The shares of common stock issued in the offering included 150,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. The net proceeds from the offering were approximately $205 million, after deducting the underwriting discount and estimated offering expenses payable by the Company.
JPM: 59.67 (+0.10), PBYI: 205.26 (+2.75)
Puma Biotechnology's underwriters exercise option to purchase 150,000 additional shares
M2 - Fri Jan 23, 8:00PM CST
Biopharmaceutical company Puma Biotechnology (NYSE
BYI) said on Thursday that the underwriters of its public offering have elected to exercise in full their option to purchase up to an additional 150,000 shares of common stock at the public offering price, less the underwriting discount. PBYI: 205.26 (+2.75)
NYSE stocks posting largest percentage increases
AP - Fri Jan 23, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at the close of trading:
AVP: 9.08 (+0.39), ORB: 28.85 (+0.21), IPHI: 19.17 (-1.48), KEY: 14.11 (-0.08), ATEN: 4.14 (-0.09), CYN: 90.32 (+0.49), WBS: 34.26 (+0.22), LUV: 43.30 (-0.20), RICE: 19.13 (-0.22), P: 15.44 (+0.45), KBR: 18.18 (+0.20), SYF: 32.80 (-0.81), DLX: 67.06 (-0.02), PBYI: 205.26 (+2.75)
Puma Biotechnology Announces Underwriters' Full Exercise of Option to Purchase Additional Shares
Business Wire - Thu Jan 22, 6:10PM CST
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced that the underwriters for its public offering of 1,000,000 shares of its common stock at $190.00 per share have elected to exercise in full their option to purchase up to an additional 150,000 shares of common stock at the public offering price, less the underwriting discount. The closing for the additional purchase of 150,000 shares is expected to take place concurrently with the closing for the initial purchase of 1,000,000 shares on January 27, 2015, subject to customary closing conditions.
JPM: 59.67 (+0.10), PBYI: 205.26 (+2.75)
Southwest Airlines and eBay are big market movers
AP - Thu Jan 22, 3:28PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Thursday on the New York Stock Exchange and the Nasdaq Stock Market:
AXP: 78.08 (-2.40), ACTG: 13.13 (+0.04), UNH: 109.44 (-0.40), FDO: 77.86 (+0.31), LUV: 43.30 (-0.20), NFLX: 466.10 (+9.37), DFS: 59.89 (+0.46), NSP: 48.91 (+1.20), EGO: 4.94 (+0.10), AMD: 3.15 (+0.03), ELD.TO: 6.15 (+0.09), VZ: 49.31 (-0.21), AAPL: 127.08 (+0.62), PBYI: 205.26 (+2.75)
4 Stocks Spiking on Unusual Volume: Puma Biotech, Nexstar and More
at The Street - Thu Jan 22, 12:48PM CST
Often when above-average volume moves into an equity, it precedes a large spike in volatility.
PFS: 18.64 (+0.09), NXST: 53.62 (+0.02), PBYI: 205.26 (+2.75), ADPT: 34.87 (+0.58)
Puma Bio prices equity offering
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 6:24AM CST
PBYI: 205.26 (+2.75)
Puma Biotechnology Prices Public Offering of Common Stock
Business Wire - Wed Jan 21, 6:13PM CST
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced the pricing of an underwritten registered public offering of 1,000,000 shares of its common stock at $190.00 per share. The Company has granted the underwriters for the offering a 30-day option to purchase up to 150,000 additional shares of its common stock at the public offering price, less the underwriting discount. The offering is expected to close on or about January 27, 2015, subject to customary closing conditions.
JPM: 59.67 (+0.10), PBYI: 205.26 (+2.75)
Puma Bio initiates equity offering
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 3:31PM CST
PBYI: 205.26 (+2.75)
Puma Biotechnology Announces Proposed Public Offering
Business Wire - Tue Jan 20, 3:23PM CST
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, today announced that it is commencing an underwritten registered public offering of 1,000,000 shares of its common stock. Puma Biotechnology intends to grant the underwriters a 30-day option to purchase up to an additional 150,000 shares of its common stock. All of the shares are being offered by Puma Biotechnology.
JPM: 59.67 (+0.10), PBYI: 205.26 (+2.75)
